Physician profile
George Smith
NPI 1164492484
$6,520.58
in general payments reported to CMS, 2019-2025
33 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $750 · 2021: $1,139 · 2022: $1,119 · 2023: $911 · 2024: $599 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.36 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,023.40 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $538.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $533.52 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $528.08 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $515.70 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $468.46 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $413.43 | 2019-2024 | |
| Pfizer INC. | $395.32 | 2019-2025 | |
| Amgen INC. | $389.27 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $250.19 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $179.04 | 2021-2025 | |
| Abiomed | $155.26 | 2021-2023 | Impella |
| Kowa Pharmaceuticals America, INC. | $142.01 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $124.18 | 2019-2025 | Evkeeza |
| Irhythm Technologies, INC. | $102.64 | 2019-2024 | Zio Xt Patch, Zio Monitor |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $98.19 | 2019-2023 | Opsumit |
| Penumbra, INC. | $89.53 | 2021 | |
| Amarin Pharma, INC. | $88.55 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $65.40 | 2025 | Assure Wcd |
| Silk Road Medical, INC. | $56.27 | 2021-2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Lexicon Pharmaceuticals, INC. | $44.68 | 2023-2024 | Inpefa |
| Abbott Laboratories | $44.32 | 2025 | Diamondback Coronary, Xience Skypoint |
| Boston Scientific Corporation | $38.73 | 2023-2025 | Avvigo Guidance System |
| Alnylam Pharmaceuticals INC. | $37.73 | 2019-2025 | Amvuttra |
| Novo Nordisk INC | $31.88 | 2023-2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $30.24 | 2020-2021 | |
| Itamar Medical INC | $29.69 | 2022-2023 | Watchpatone |
| Bridgebio Pharma, INC. | $26.70 | 2025 | Attruby |
| Stryker Corporation | $19.43 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $16.33 | 2019 | |
| Esperion Therapeutics, INC. | $15.94 | 2022 | |
| Scpharmaceuticals INC. | $14.22 | 2024 | |
| Akcea Therapeutics, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.